Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/9/2012

CRANBURY, N.J., Nov. 9, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2013 financial results on Wednesday, November 14, 2012 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2012, which will include discussion of the results of operations in greater detail and an update on corporate developments.Schedule for the Financial Results Press Release, Conference Call / Webcast

  • Q1 Fiscal Year 2013 Financial Results Press Release
  • 11/14/2012 at 7:30 a.m. ET

     

  • Q1 Fiscal Year 2013 Conference Call-Live
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 11/14/2012 at 11:00 a.m. ET
    1-888-428-9490
    1-719-325-2354

    9649528

     

  • Q1 Fiscal Year 2013 Conference Call-Replay
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 11/14/2012-11/20/2012
    1-888-203-1112
    1-719-457-0820
    9649528

     

  • Webcast Live and Replay Access
  • http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

    section of Palatin's website at http://www.palatin.com. About Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.


    '/>"/>
    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1

    Related biology technology :

    1. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
    3. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    4. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    5. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    6. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    7. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    8. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    9. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    10. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
    (Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
    (Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
    (Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
    Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
    ... the leading management consulting firm specializing in the pharmaceutical ... industry veterans Jon W. McGarity and David Lilley as ... with John Campbell, CEO of Campbell Alliance, and the ... and midsize client companies. They will focus on ...
    ... for Discovery and Validation of New Biomarker Panels ... Rules-Based Medicine, Incorporated (RBM), the world,s leading multiplexed ... the most comprehensive collection of quantitative immunoassays for ... drug and diagnostic development. The new service, DiscoveryMAP(TM) ...
    ... REGENSBURG, Germany, June 17 , - ... Reproductive Medicine , - MedITEX from 28 ... 87/88) , The IT consulting company CRITEX, ... for in vitro fertilisation, MedITEX IVF,at the 25th Annual Meeting of ...
    Cached Biology Technology:Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents 2Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents 3Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents 4Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3New IVF Software MedITEX to be Presented at the ESHRE Exhibition 2
    (Date:4/22/2014)... team of Yale researchers will lead a five-year, $3 ... rain events is affecting the transport of dissolved organic ... they say could alter the chemical composition and water ... With funding from the National Science Foundation,s MacroSystems Biology ... across the watershed, which begins in Canada and runs ...
    (Date:4/22/2014)... 2014) Biotechnology scientists must be aware of the ... licensing guidelines, according to a new paper from Rice ... the current issue of the journal Regenerative Medicine ... U.S. Supreme Court ruling in the case Association for ... genes are unpatentable. The court case and rulings garnered ...
    (Date:4/22/2014)... University of Massachusetts Amherst and the Instituto Nacional de ... they have discovered a new genus and species of ... in the Amazonia State of Brazil. , Professor Cristina ... Jos Antnio Alves-Gomes of INPA, describe the new bluntnose ... Proceedings of the Natural Sciences of Philadelphia . ...
    Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2
    ... continued support of the Colorado BioScience Association today, ... showcase event in Colorado to be held at the ... in the goals and community that is fostered by the ... of BiOptix.   "As Colorado continues to expand its footprint ...
    ... way to prevent inflammation and bone loss surrounding the ... enzyme GSK3b, which plays an important role in directing ... School of Dentistry researcher David Scott, PhD, and his ... Molecular Medicine . The finding not only has implications ...
    ... PORTLAND, Ore. A novel human liver-chimeric mouse model developed ... made possible a research breakthrough at Seattle Biomedical Research Institute ... of human malaria. The study findings are published ... photos were selected to appear in "Scientific Show Stoppers" on ...
    Cached Biology News:BiOptix Participates in Leading Life Sciences Event BioWest 2012 2'Humanized' mice developed at OHSU enable malaria research breakthrough at Seattle BioMed 2'Humanized' mice developed at OHSU enable malaria research breakthrough at Seattle BioMed 3
    Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
    ... the Lone Wolf valve has the highest ... valve available on the market. This VSO ... performance, and ensures maximum accuracy., Achieves ... control and patient comfort. , Maintains ideal ...
    ... Precision Slide Table is designed for moving ... design provides maximum force output while limiting ... sets of stainless steel ball bearings guided ... or self-compensating shock absorbers provide energy absorption ...
    Hamster serum...
    Biology Products: